Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion.

Serum dehydroepiandrosterone declines with age. Whether this represents a harmful deficiency or an age-related adaptation is not known. Dehydroepiandrosterone replacement in adrenal insufficiency, a state of pathological loss of dehydroepiandrosterone production, improves well-being, mood, and sexuality. To determine the effects of dehydroepiandrosterone in healthy men with a physiological, age-related decline in serum dehydroepiandrosterone sulfate, we conducted a double blind cross-over study in 22 healthy male volunteers (age range, 50-69 yr) with endogenous dehydroepiandrosterone sulfate levels below 4.1 micromol/liter (1500 ng/ml) receiving 4 months of dehydroepiandrosterone (50 mg/d) and 4 months of placebo treatment in random order, with a 1-month washout period. Dehydroepiandrosterone treatment increased serum dehydroepiandrosterone and dehydroepiandrosterone sulfate to concentrations usually found in young men. Circulating androgen levels did not change; however, androgen metabolites increased, indicating enhanced peripheral androgen synthesis. At baseline, psychometric assessment revealed normal well-being and sexuality scores. After 4 months of dehydroepiandrosterone, no effect on sexuality was observed, whereas some mood scores improved slightly, but were not significantly different from scores after placebo. Compared with placebo, dehydroepiandrosterone had no effect on serum lipids, bone markers, body composition, or exercise capacity. Thus, in contrast to previous findings in adrenal insufficiency, we found no obvious benefit of 4 months of dehydroepiandrosterone supplementation in healthy men with a physiological decline of dehydroepiandrosterone production.

[1]  F. Huppert,et al.  Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. , 2000, The Journal of clinical endocrinology and metabolism.

[2]  E. Baulieu,et al.  Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Barnhart,et al.  The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. , 2000, The Journal of clinical endocrinology and metabolism.

[4]  K. Barnhart,et al.  The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life , 1999 .

[5]  D B Allison,et al.  Validation of bioimpedance analysis as a measure of change in body cell mass as estimated by whole-body counting of potassium in adults. , 1999, JPEN. Journal of parenteral and enteral nutrition.

[6]  M. Bidlingmaier,et al.  Dehydroepiandrosterone replacement in women with adrenal insufficiency. , 1999, The New England journal of medicine.

[7]  B. Allolio,et al.  Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. , 1999, The Journal of clinical endocrinology and metabolism.

[8]  M. Flynn,et al.  Dehydroepiandrosterone replacement in aging humans. , 1999, The Journal of clinical endocrinology and metabolism.

[9]  F. Salek,et al.  DHEA and DHEA‐S: A Review , 1999, Journal of clinical pharmacology.

[10]  O. Wolkowitz,et al.  Double-blind treatment of major depression with dehydroepiandrosterone. , 1999, The American journal of psychiatry.

[11]  M. Genovese,et al.  A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus , 1999, Lupus.

[12]  M. Marberger,et al.  Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. , 1999, Urology.

[13]  R. Haubrich,et al.  The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age‐advanced men and women , 1998, Clinical endocrinology.

[14]  F. Kimura,et al.  A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy , 1998, Neurology.

[15]  N. Santoro,et al.  Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. , 1998, Fertility and sterility.

[16]  F. Svec,et al.  The Actions of Exogenous Dehydroepiandrosterone in Experimental Animals and Humans , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  J. Goméz,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women , 2022 .

[18]  P. Chanson,et al.  Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. , 1997, The Journal of clinical endocrinology and metabolism.

[19]  F. Labrie,et al.  Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. , 1997, The Journal of clinical endocrinology and metabolism.

[20]  J. Goméz,et al.  Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. , 1997, The Journal of endocrinology.

[21]  E. Engleman,et al.  Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. , 1995, Arthritis and rheumatism.

[22]  D. Johnston,et al.  Comparison of measurements of body composition by total body potassium, bioimpedance analysis, and dual-energy X-ray absorptiometry in hypopituitary adults before and during growth hormone treatment. , 1995, The American journal of clinical nutrition.

[23]  A. Straughn,et al.  Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. , 1995, Fertility and sterility.

[24]  J. Goméz,et al.  Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. , 1994, The Journal of clinical endocrinology and metabolism.

[25]  D. Gagné,et al.  Widespread tissue distribution of steroid sulfatase, 3β-hydroxysteroid dehydrogenase/Δ5-Δ4isomerase(3β-HSD), 17β-HSD5α-reductase and aromatase activities in the rhesus monkey , 1994, Molecular and Cellular Endocrinology.

[26]  S. Yen,et al.  Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. , 1994, The Journal of clinical endocrinology and metabolism.

[27]  M. Seibel,et al.  Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. , 1989, The Journal of rheumatology.

[28]  M J McCutcheon,et al.  Electrical impedance in assessing human body composition: the BIA method. , 1988, The American journal of clinical nutrition.

[29]  G. Huston The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[30]  N. Orentreich,et al.  Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. , 1984, The Journal of clinical endocrinology and metabolism.

[31]  G. Hodgen,et al.  Adrenarche: a survey of rodents, domestic animals, and primates. , 1978, Endocrinology.

[32]  S. Wallenstein,et al.  The analysis of the two-period repeated measurements crossover design with application to clinical trials. , 1977, Biometrics.

[33]  L. Covi,et al.  SCL-90: an outpatient psychiatric rating scale--preliminary report. , 1973, Psychopharmacology bulletin.